Skip to main content
logo
Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
2.750
+0.100 (3.77%)
At close: Oct 17, 2025, 4:00 PM EDT
2.740
-0.010 (-0.36%)
After-hours: Oct 17, 2025, 7:55 PM EDT

Esperion Therapeutics Revenue

Esperion Therapeutics had revenue of $82.39M in the quarter ending June 30, 2025, with 11.58% growth. This brings the company's revenue in the last twelve months to $268.13M, down -3.48% year-over-year. In the year 2024, Esperion Therapeutics had annual revenue of $332.31M with 185.66% growth.

Revenue (ttm)
$268.13M
Revenue Growth
-3.48%
P/S Ratio
2.01
Revenue / Employee
$881,990
Employees
304
Market Cap
636.96M

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2024332.31M215.98M185.66%
Dec 31, 2023116.33M40.86M54.14%
Dec 31, 202275.48M-2.97M-3.79%
Dec 31, 202178.45M-149.10M-65.52%
Dec 31, 2020227.55M79.18M53.37%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company NameRevenue
UnitedHealth Group422.82B
Johnson & Johnson92.15B
Merck & Co.63.62B
AbbVie58.33B
AstraZeneca56.50B
Novartis AG55.19B
Eli Lilly and Company53.26B
Novo Nordisk49.11B
Revenue Rankings

ESPR News

More News